Calquence (acalabrutinib)

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

BTK inhibitor

Related drugs:

‹

›

No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: A1 - Approval obinutuzumab + acalabrutinib Sensitive : A1	obinutuzumab + acalabrutinib Sensitive: A1 - Approval obinutuzumab + acalabrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2
BTK C481S	Chronic Lymphocytic Leukemia	BTK C481S	Chronic Lymphocytic Leukemia	acalabrutinib Resistant: A2 - Guideline acalabrutinib Resistant : A2	acalabrutinib Resistant: A2 - Guideline acalabrutinib Resistant : A2
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2	acalabrutinib Sensitive: A2 - Guideline acalabrutinib Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + acalabrutinib Sensitive: A2 - Guideline rituximab + acalabrutinib Sensitive : A2	rituximab + acalabrutinib Sensitive: A2 - Guideline rituximab + acalabrutinib Sensitive : A2
Chr del(17)(p13.1)	Chronic Lymphocytic Leukemia	Chr del(17)(p13.1)	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: B - Late Trials acalabrutinib Sensitive : B	acalabrutinib Sensitive: B - Late Trials acalabrutinib Sensitive : B
Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	Chr del(11)(q22.3)	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: B - Late Trials acalabrutinib Sensitive : B	acalabrutinib Sensitive: B - Late Trials acalabrutinib Sensitive : B
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: B - Late Trials acalabrutinib Sensitive : B	acalabrutinib Sensitive: B - Late Trials acalabrutinib Sensitive : B
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: B - Late Trials obinutuzumab + acalabrutinib Sensitive : B	obinutuzumab + acalabrutinib Sensitive: B - Late Trials obinutuzumab + acalabrutinib Sensitive : B
Chr del(17)(p13.1)	Chronic Lymphocytic Leukemia	Chr del(17)(p13.1)	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: B - Late Trials obinutuzumab + acalabrutinib Sensitive : B	obinutuzumab + acalabrutinib Sensitive: B - Late Trials obinutuzumab + acalabrutinib Sensitive : B
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab + acalabrutinib Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab + acalabrutinib Sensitive : C2	venetoclax + obinutuzumab + acalabrutinib Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab + acalabrutinib Sensitive : C2
NLRC5 mutation	Mantle Cell Lymphoma	NLRC5 mutation	Mantle Cell Lymphoma	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3
B2M mutation	Mantle Cell Lymphoma	B2M mutation	Mantle Cell Lymphoma	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3
CARD11 mutation	Mantle Cell Lymphoma	CARD11 mutation	Mantle Cell Lymphoma	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3
ITGA4 overexpression	Chronic Lymphocytic Leukemia	ITGA4 overexpression	Chronic Lymphocytic Leukemia	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3
Chr del(17)(p13.1)	Small Lymphocytic Lymphoma	Chr del(17)(p13.1)	Small Lymphocytic Lymphoma	acalabrutinib Sensitive: C3 – Early Trials acalabrutinib Sensitive : C3	acalabrutinib Sensitive: C3 – Early Trials acalabrutinib Sensitive : C3
Chr del(11)(q22.3)	Small Lymphocytic Lymphoma	Chr del(11)(q22.3)	Small Lymphocytic Lymphoma	acalabrutinib Sensitive: C3 – Early Trials acalabrutinib Sensitive : C3	acalabrutinib Sensitive: C3 – Early Trials acalabrutinib Sensitive : C3
TP53 mutation	Mantle Cell Lymphoma	TP53 mutation	Mantle Cell Lymphoma	rituximab + lenalidomide + acalabrutinib Sensitive: C3 – Early Trials rituximab + lenalidomide + acalabrutinib Sensitive : C3	rituximab + lenalidomide + acalabrutinib Sensitive: C3 – Early Trials rituximab + lenalidomide + acalabrutinib Sensitive : C3
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3

Calquence (acalabrutinib)

Associations
(41)

Associations
(41)

Calquence (acalabrutinib)

Associations(41)

Associations(41)

Associations
(41)

Associations
(41)